In these single and multiple ascending-dose Phase 1 studies, we investigated the safety, PK, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers and a subject with mild atopic asthma. Here, IL17A is linked to atopic asthma.